JP2023522956A5 - - Google Patents
Info
- Publication number
- JP2023522956A5 JP2023522956A5 JP2022564128A JP2022564128A JP2023522956A5 JP 2023522956 A5 JP2023522956 A5 JP 2023522956A5 JP 2022564128 A JP2022564128 A JP 2022564128A JP 2022564128 A JP2022564128 A JP 2022564128A JP 2023522956 A5 JP2023522956 A5 JP 2023522956A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- vitamin
- thyroid hormone
- pharmaceutical composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013960P | 2020-04-22 | 2020-04-22 | |
| US63/013,960 | 2020-04-22 | ||
| US202063088523P | 2020-10-07 | 2020-10-07 | |
| US63/088,523 | 2020-10-07 | ||
| US202163135118P | 2021-01-08 | 2021-01-08 | |
| US63/135,118 | 2021-01-08 | ||
| PCT/US2021/028675 WO2021216896A1 (en) | 2020-04-22 | 2021-04-22 | Treatment of conditions associated with thyroid hormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522956A JP2023522956A (ja) | 2023-06-01 |
| JP2023522956A5 true JP2023522956A5 (enExample) | 2024-05-01 |
Family
ID=78270024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564128A Pending JP2023522956A (ja) | 2020-04-22 | 2021-04-22 | 甲状腺ホルモンと関連する病態の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230149410A1 (enExample) |
| EP (1) | EP4138809A4 (enExample) |
| JP (1) | JP2023522956A (enExample) |
| KR (1) | KR20230015906A (enExample) |
| CN (1) | CN115916177A (enExample) |
| AU (1) | AU2021260956A1 (enExample) |
| BR (1) | BR112022021420A2 (enExample) |
| CA (1) | CA3175608A1 (enExample) |
| IL (1) | IL297453A (enExample) |
| MX (1) | MX2022013140A (enExample) |
| PH (1) | PH12022553118A1 (enExample) |
| WO (1) | WO2021216896A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025522112A (ja) * | 2022-07-11 | 2025-07-10 | プリズム・エルエルシー | アラン・ハーンドン・ダドリー症候群を治療するための方法 |
| CA3261855A1 (en) * | 2022-07-11 | 2024-01-18 | PriZm, LLC | METHODS AND FORMULATIONS OF GENE THERAPY, AND OF COMBINATION OF GENE THERAPY WITH DITPA THERAPY, FOR ALLAN-HERNDON-DUDLEY SYNDROME |
| US20240350591A1 (en) * | 2023-04-12 | 2024-10-24 | Xygenyx Inc. | Composition and methods of treatment using synergistically-enhanced supplementation |
| CN121910745B (zh) * | 2026-03-23 | 2026-05-26 | 暨南大学 | N-乙酰神经氨酸在制备治疗甲基苯丙胺成瘾的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1243101A (en) * | 1999-10-28 | 2001-05-08 | Cary Pharmaceuticals Inc. | High dose folic acid for the treatment of hyperhomocysteinemia |
| IT1320776B1 (it) * | 2000-08-07 | 2003-12-10 | Giampiero Valletta | Composizione farmaceutica a base di un'associazione vitaminica per laterapia delle cefalee primarie |
| HRP20160406T1 (hr) * | 2009-07-10 | 2016-05-20 | Linzy O. Scott Iii | Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima |
| WO2012171065A1 (en) * | 2011-06-17 | 2012-12-20 | Esra Ogru | Treatment of allan-herndon-dudley syndrome with 3,5-diiodothyropropionic acid (ditpa). |
| US10640748B2 (en) * | 2014-12-24 | 2020-05-05 | Neuorphan Pty Ltd | Oligodendroglial cell culturing methods and in methods for treating neurodegenerative disorders by using thyroid hormones or analogues |
| US20160339086A1 (en) * | 2015-05-19 | 2016-11-24 | Suzy Cohen | Compositions and methods for treating thyroid disease |
-
2021
- 2021-04-22 EP EP21793379.5A patent/EP4138809A4/en active Pending
- 2021-04-22 CA CA3175608A patent/CA3175608A1/en active Pending
- 2021-04-22 US US17/996,865 patent/US20230149410A1/en active Pending
- 2021-04-22 PH PH1/2022/553118A patent/PH12022553118A1/en unknown
- 2021-04-22 AU AU2021260956A patent/AU2021260956A1/en not_active Abandoned
- 2021-04-22 CN CN202180030618.0A patent/CN115916177A/zh active Pending
- 2021-04-22 JP JP2022564128A patent/JP2023522956A/ja active Pending
- 2021-04-22 MX MX2022013140A patent/MX2022013140A/es unknown
- 2021-04-22 IL IL297453A patent/IL297453A/en unknown
- 2021-04-22 BR BR112022021420A patent/BR112022021420A2/pt unknown
- 2021-04-22 KR KR1020227039930A patent/KR20230015906A/ko active Pending
- 2021-04-22 WO PCT/US2021/028675 patent/WO2021216896A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Markham | Savolitinib: first approval | |
| CN107921054B (zh) | 细胞内atp增强剂 | |
| Kakuda et al. | Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two‐way crossover trial | |
| PE20050438A1 (es) | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos | |
| FI94094B (fi) | Kantajakoostumus kestovaikutteiselle lääkeainevalmisteelle | |
| JP2022539077A5 (enExample) | ||
| JP2004217669A (ja) | 抗糖尿病用医薬およびその製造方法 | |
| FI3990005T3 (fi) | Pegyloitu kystationiini-beta-syntaasi entsyymihoitoa varten homokystinurian hoitamiseksi | |
| Gupta et al. | The effect of a high‐fat meal on the pharmacokinetics of ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma | |
| TW200528104A (en) | Combination therapy for hcv infection | |
| Sonnenfeld et al. | Type II interferon induction and passive transfer depress the murine cytochrome P-450 drug metabolism system | |
| Zwitter et al. | Phase I–II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer | |
| Nguyen et al. | Discontinuation of folic acid supplementation in young patients with sickle cell anemia | |
| MXPA97007046A (en) | Compositions comprising nicotinylalanin and a glitin or vitamin conjugation inhibitor | |
| JP2021502379A5 (enExample) | ||
| Trimarchi et al. | Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients | |
| WO2003043608A1 (en) | Process for the preparation of tablets comprising s-adenosylmethionine | |
| Fountzilas et al. | A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study | |
| JP2668214B2 (ja) | Ａｉｄｓ治療薬 | |
| US10231974B2 (en) | Pharmaceutical composition effective in preventing the adverse effects associated with the prolonged use of dihydrofolate reductase inhibitors | |
| Harned et al. | Effects of passive transfer and induction of gamma (type II immune) interferon preparations on the metabolism of diphenylhydantoin by murine cytochrome P-450 | |
| IL276437B1 (en) | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for the treatment of diffuse large B-cell lymphoma | |
| JPH0337521B2 (enExample) | ||
| NO950950L (no) | Farmasöytisk preparat | |
| Misson et al. | Therapeutic advances: protease inhibitors for the treatment of HIV‐1 infection |